NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) issued its earnings results on Tuesday, February, 20th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The firm's revenue was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.12) earnings per share. View TherapeuticsMD's Earnings History.

9 brokerages have issued 12 month price targets for TherapeuticsMD's stock. Their forecasts range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.50 in the next twelve months. View Analyst Ratings for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 57,501,783 shares, an increase of 0.8% from the March 15th total of 57,941,715 shares. Based on an average daily trading volume, of 1,926,644 shares, the days-to-cover ratio is presently 29.8 days. Currently, 33.1% of the shares of the stock are sold short.

Some companies that are related to TherapeuticsMD include Supernus Pharmaceuticals (SUPN), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Heron Therapeutics (HRTX), AnaptysBio (ANAB), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Corcept Therapeutics (CORT), Motif (MTFB), Aimmune Therapeutics (AIMT), Insmed (INSM), Cambrex (CBM), MyoKardia (MYOK) and Arena Pharmaceuticals (ARNA).

Press coverage about TXMD stock has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.09 on Accern's scale. They also assigned news stories about the company an impact score of 46.01 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $5.85.

TherapeuticsMD has a market capitalization of $1.24 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]